We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

European Patent Office Backs AstraZeneca's Symbicort Patent

Law360 (March 9, 2005, 12:00 AM EST) -- The European Patent Office has upheld the validity of the European combination patent for Swedish-U.K. drug maker AstraZeneca’s asthma treatment Symbicort, which had faced a challenge by several generic manufacturers.

As a result, no generic manufacturer can launch an equivalent product until AstraZeneca’s data exclusivity has expired or the generic company has submitted its own regulatory package, utilizing its own clinical data.

Astrazeneca has data protection for the drug in most major European until 2010. The European combination patent expires in 2012 with extension by supplementary...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.